sorafenib has been researched along with Diathesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albandea-Rodríguez, D; Arconada-Luque, E; Belandia, B; Encinar, JA; Fernández-Aroca, DM; Muñoz, I; Ortega-Muelas, M; Pascual-Serra, R; Roche, O; Ruiz-Hidalgo, MJ; Sánchez-Pérez, I; Sánchez-Prieto, R | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
2 other study(ies) available for sorafenib and Diathesis
| Article | Year |
|---|---|
ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology.
Topics: Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Movement; Disease Susceptibility; Epidermal Growth Factor; Flow Cytometry; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 7; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Structure-Activity Relationship | 2021 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |